FDA requested in August 2009 (food and Drug Administration) and its own American sales organization currently is based, to market the drug for approval in the United States. * PecFent was previously called NasalFent. Please contact for more information: Archimedes PharmGermany GmbH: Armin Rath, + 49 621 12470410, change communication: TIMEA Koszeghi + 49 69 97501 163, notes for the editors: the company Archimedes Pharma Archimedes Pharma (“Archimedes”) is a specialty pharmaceutical company with a growing portfolio of finished medicinal product for doctors in the main European countries. Archimedes focuses on the areas of Oncology, pain, Neurology and intensive care medicine and is currently represented by a whole range of medicines in the United Kingdom, as well as in France, Germany and Ireland; an extension of the business presence is planned for 2010 to Spain and the United States. Products, the Archimedes already offered in Europe, include: Gliadel, a biodegradable drug carrier impregnated with by carmustine against highly malignant gliomas; Zomorph, an orally administered morphine with delayed release against moderate to severe pain, especially in cancer patients; Oramorph, a liquid fast effective morphine drug in single dose containers, which is indicated also in strong to strongest pain; Apomorphine of Archimedes to the injection against motor fluctuations in Parkinson’s disease in the advanced stage, as well as Pabrinex, a potent multivitamin for symptomatic treatment of malnutrition, especially after alcohol abuse.
Archimedes also developed a range of robust, high-quality private drugs for pain therapy and intensive care medicine, as well as for the treatment of Parkinson’s disease. The company spends his unique method of active ingredient release it already proven molecules on, their market potential due to their previous formulation to date not could be exploited. This approach keeps the development risks for the company and offers at the same time considerable clinical and commercial benefits. PecFent is a real milestone for Archimedes: an innovative and highly differentiated fentanyl citrate nasal spray for treating of cancer breakthrough pain, now with positive opinion from the CHMP.